We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Pradeep Natarajan

Pradeep Natarajan MD, MMSc

Director of Preventive Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Associate Member, Broad Institute of Harvard and MIT, Cambridge, Massachusetts

Pradeep Natarajan is Director of Preventive Cardiology at Massachusetts General Hospital, Assistant Professor of Medicine at Harvard Medical School, and Associate Member of the Broad Institute of Harvard and MIT.

He received his BA in molecular biology with Honors and Phi Beta Kappa in 2004 from the University of California, Berkeley. He received his MD with Alpha Omega Alpha in 2008 from the University of California, San Francisco. He received his MMSc in biomedical informatics in 2015 from Harvard Medical School. Dr. Natarajan completed his internship and residency in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School in 2011. He completed his clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, Harvard Medical School in 2015.

Dr. Natarajan researches the germline and somatic genetic bases of human atherosclerosis using genetic epidemiology, large-scale sequencing studies, genotype-driven human investigation, and genetic testing implementation. In addition to his research efforts, Dr. Natarajan is a clinical cardiologist focusing on heart attack prevention, cardiovascular risk reduction, premature heart attack, lipid disorders, and cardiovascular genetics based at the MGH Cardiovascular Disease Prevention Center.

Disclosures

Dr. Natarajan reports investigator-initiated grants from Amgen, Apple, AstraZeneca, and Boston Scientific, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech, and Novartis, and spousal salary from Vertex, all unrelated to the present commentary.

Recent Contributions to PracticeUpdate:

  1. Clonal Hematopoiesis and Risk of Progression of HFrEF